Valéry Attignon
About
Valéry Attignon is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology.
According to data from OpenAlex, Valéry Attignon has authored 34 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cancer Research, 17 papers in Pulmonary and Respiratory Medicine and 17 papers in Oncology. Recurrent topics in Valéry Attignon's work include Cancer Genomics and Diagnostics (18 papers), Lung Cancer Treatments and Mutations (5 papers) and Genetic factors in colorectal cancer (4 papers). Valéry Attignon is often cited by papers focused on Cancer Genomics and Diagnostics (18 papers), Lung Cancer Treatments and Mutations (5 papers) and Genetic factors in colorectal cancer (4 papers). Valéry Attignon collaborates with scholars based in France, Belgium and Germany. Valéry Attignon's co-authors include Daniel Pissaloux, Isabelle Treilleux, Isabelle Ray‐Coquard, Christophe Caux, Nathalie Bendriss‐Vermare, Jacobus Pfisterer, Qing Wang, Florence Joly, Dimitri Psimaras and Olivier Trédan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.
In The Last Decade
Valéry Attignon
31 papers receiving 229 citations
Peers
Valéry Attignon
Dennis Döcker Germany
Timothy G. Bowler United States
Shinobu Noji Japan
Katharina Prochazka Austria
Caroline Louis‐Brennetot France
Andrea Bier Germany
Alex Cazes France
Amy K. Bruzek United States
David Ancona‐Lezama United States
Hwa Jin Cho South Korea
Citations per year, relative to Valéry Attignon Valéry Attignon (= 1×)
peers
Dennis Döcker
Countries citing papers authored by Valéry Attignon
Since
Specialization
Citations
This map shows the geographic impact of Valéry Attignon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valéry Attignon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valéry Attignon more than expected).
Fields of papers citing papers by Valéry Attignon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Valéry Attignon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valéry Attignon. The network helps show where Valéry Attignon may publish in the future.
Co-authorship network of co-authors of Valéry Attignon
This figure shows the co-authorship network connecting the top 25 collaborators of Valéry Attignon. A scholar is included among the top collaborators of Valéry Attignon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valéry Attignon. Valéry Attignon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Treilleux, Isabelle, Valentin Wucher, Macarena Villagrán‐García, et al.. (2025). Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes. Neurology Neuroimmunology & Neuroinflammation. 12(2). e200367–e200367.
2.
Larrouquère, Louis, Pierre-Étienne Heudel, Érika Cosset, et al.. (2024). 251P Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis. ESMO Open. 9. 103272–103272.
3.
Vanacker, Hélène, Isabelle Treilleux, Camille Schiffler, et al.. (2024). p4EBP1 staining predicts outcome in ER-positive endocrine-resistant metastatic breast cancer patients treated with everolimus and exemestane. British Journal of Cancer. 130(4). 613–619.
4.
Dufresne, Armelle, Valéry Attignon, Anthony Ferrari, et al.. (2024). Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel. Cancer Medicine. 13(7). e7115–e7115.
5.
Vanacker, Hélène, Alexandra Meurgey, Julien Bollard, et al.. (2024). Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics. Journal of Immunotherapy. 48(1). 27–31.
6.
Brahmi, Mehdi, Olivier Trédan, Nicolas Penel, et al.. (2023). Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.. Journal of Clinical Oncology. 41(16_suppl). 11545–11545.
7.
Tourneau, Christophe Le, Sophie Cousin, Maud Toulmonde, et al.. (2023). 138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations. Annals of Oncology. 34. S236–S236.
8.
Magné, Nicolas, Jérôme Fayette, Élisabeth Daguenet, et al.. (2021). Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub‐analysis of the ProfiLER protocol. Head & Neck. 43(12). 3899–3910.
9.
Fraunhoffer, Nicolás A., Abdessamad El-Kaoutari, Odile Gayet, et al.. (2021). Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Cancers. 13(10). 2473–2473.
10.
Karabajakian, Andy, Jebrane Bouaoud, Maud Kamal, et al.. (2021). Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. Oral Oncology. 119. 105368–105368.
11.
Attignon, Valéry, Domenico Ferraioli, Pierre Méeus, et al.. (2021). Molecular Characterization of Ovarian Yolk Sac Tumor (OYST). Cancers. 13(2). 220–220.
12.
Brahmi, Mehdi, Hélène Vanacker, Lauriane Eberst, et al.. (2020). Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial. Translational Oncology. 13(12). 100870–100870.
13.
Bachelot, Thomas, Isabelle Treilleux, Camille Schiffler, et al.. (2019). mTORC1 activation assessed in metastatic sample to predict outcome in patients with metastatic breast cancer treated with everolimus-exemestan: Results from the SAFIRTOR study.. Journal of Clinical Oncology. 37(15_suppl). 1024–1024.
14.
Treilleux, Isabelle, Coline Couillault, Daniel Pissaloux, et al.. (2018). Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathologica. 135(4). 569–579.
15.
Négrier, Sylvie, et al.. (2018). Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports. Journal of Medical Case Reports. 12(1). 351–351.
16.
Blay, Jean‐Yves, Véronique Corset, Isabelle Treilleux, et al.. (2017). PROFILER 02 - A multicentric, prospective cohort study aiming to evaluate the added value of a large molecular profiling panel (315 cancer-related gene panel [FoundationOne]) versus a limited molecular profiling panel (74 cancer-related gene panel [CONTROL]) in advanced solid tumours. Annals of Oncology. 28. vii4–vii4.
17.
Cassier, Philippe A., Christelle de la Fouchardière, Pierre Guibert, et al.. (2017). Actionable molecular alterations in advanced biliary tract carcinomas: Preliminary data from the ProfiLER program (NCT01774409). Annals of Oncology. 28. v247–v247.
18.
Ray‐Coquard, Isabelle, Véronique Corset, Christian Baudet, et al.. (2017). Actionable molecular alterations in advanced gynecologic malignancies: First results from the ProfiLER program (NCT01774409) in France. Annals of Oncology. 28. v333–v333.
19.
Gonçalvès, Anthony, Thomas Bachelot, Amélie Lusque, et al.. (2017). Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304). Cancer Research. 77(4_Supplement). PD1–8.
20.
Joly, Marie‐Odile, Valéry Attignon, Jean‐Christophe Saurin, et al.. (2014). Somatic MMR Gene Mutations as a Cause for MSI-H Sebaceous Neoplasms in Muir-Torre Syndrome-Like Patients. Human Mutation. 36(3). 292–295.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Dennis Döcker Breakdown of academic impact, for papers by Timothy G. Bowler Breakdown of academic impact, for papers by Shinobu Noji Breakdown of academic impact, for papers by Katharina Prochazka Breakdown of academic impact, for papers by Caroline Louis‐Brennetot Breakdown of academic impact, for papers by Andrea Bier Breakdown of academic impact, for papers by Alex Cazes Breakdown of academic impact, for papers by Amy K. Bruzek Breakdown of academic impact, for papers by David Ancona‐Lezama Breakdown of academic impact, for papers by Hwa Jin Cho